As of 2025-10-18, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is -22.72. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 2,740.01 mil USD. TVTX's TTM EBITDA according to its financial statements is -120.57 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 17.3x | 16.4x |
| Forward P/E multiples | 13.1x - 19.3x | 14.7x |
| Fair Price | (22.36) - (26.79) | (24.45) |
| Upside | -181.8% - -198.1% | -189.5% |
| Date | EV/EBITDA |
| 2025-10-16 | -22.87 |
| 2025-10-15 | -22.38 |
| 2025-10-14 | -21.85 |
| 2025-10-13 | -21.90 |
| 2025-10-10 | -21.13 |
| 2025-10-09 | -21.80 |
| 2025-10-08 | -21.90 |
| 2025-10-07 | -21.38 |
| 2025-10-06 | -21.84 |
| 2025-10-03 | -20.74 |
| 2025-10-02 | -20.43 |
| 2025-10-01 | -20.85 |
| 2025-09-30 | -20.20 |
| 2025-09-29 | -20.30 |
| 2025-09-26 | -21.23 |
| 2025-09-25 | -20.72 |
| 2025-09-24 | -20.57 |
| 2025-09-23 | -20.44 |
| 2025-09-22 | -21.33 |
| 2025-09-19 | -20.90 |
| 2025-09-18 | -20.41 |
| 2025-09-17 | -20.01 |
| 2025-09-16 | -19.36 |
| 2025-09-15 | -19.54 |
| 2025-09-12 | -19.88 |
| 2025-09-11 | -21.01 |
| 2025-09-10 | -22.72 |
| 2025-09-09 | -18.53 |
| 2025-09-08 | -18.20 |
| 2025-09-05 | -18.53 |
| 2025-09-04 | -18.16 |
| 2025-09-03 | -17.02 |
| 2025-09-02 | -15.95 |
| 2025-08-29 | -15.46 |
| 2025-08-28 | -15.61 |
| 2025-08-27 | -15.42 |
| 2025-08-26 | -15.42 |
| 2025-08-25 | -15.27 |
| 2025-08-22 | -15.78 |
| 2025-08-21 | -15.68 |
| 2025-08-20 | -15.81 |
| 2025-08-19 | -15.56 |
| 2025-08-18 | -16.40 |
| 2025-08-15 | -16.44 |
| 2025-08-14 | -16.00 |
| 2025-08-13 | -15.87 |
| 2025-08-12 | -15.40 |
| 2025-08-11 | -15.30 |
| 2025-08-08 | -15.05 |
| 2025-08-07 | -15.03 |